Background: People with dementia are extremely vulnerable in hospital and unscheduled admissions should be avoided if possible.
Aims: To identify any predictors of general hospital admission in people with dementia in a well-characterised national prospective cohort study.
Method: A cohort of 730 persons with dementia was drawn from the Scottish Dementia Research Interest Register (47.8% female; mean age 76.3 years, s.d. = 8.2, range 50-94), with a mean follow-up period of 1.2 years.
Results: In the age- and gender-adjusted multivariable model (n = 681; 251 admitted), Neuropsychiatric Inventory score (hazard ratio per s.d. disadvantage 1.21, 95% CI 1.08-1.36) was identified as an independent predictor of admission to hospital.
Conclusions: Neuropsychiatric symptoms in dementia, measured using the Neuropsychiatric Inventory, predict non-psychiatric hospital admission of people with dementia. Further studies are merited to test whether interventions to reduce such symptoms might reduce unscheduled admissions to acute hospitals.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1192/bjp.bp.113.137166 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The association of seizure control with neuropathology in dementia.
Brain
January 2025
Comprehensive Epilepsy Program, Department of Neurology, University of Virginia, Charlottesville, Virginia 22908, USA.
Seizures in people with dementia (PWD) are associated with faster cognitive decline and worse clinical outcomes. However, the relationship between ongoing seizure activity and postmortem neuropathology in PWD remains unexplored. We compared post-mortem findings in PWD with active, remote, and no seizures using multicentre data from 39 Alzheimer's Disease Centres from 2005 to 2021.
View Article and Find Full Text PDFNorthern Lights Neuroscience Symposium 2024: Expanding Spectrum of Common Dementia Disorders.
Free Neuropathol
January 2024
The Northern Lights Neuroscience Symposium 2024 "Expanding Spectrum of Common Dementia Disorders" was held in Hanasaari, Helsinki (Espoo), Finland on September 26-27, 2024. The meeting was jointly organised by the Scandinavian Neuropathological Society (chair Olivera Casar-Borota) and University of Helsinki. Drs.
View Article and Find Full Text PDFLow serum serotonin is associated with functional decline, mild behavioural impairment and brain atrophy in dementia-free subjects.
Brain Commun
January 2025
Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, S117600 Singapore, Singapore.
Brain serotonin dysregulation is associated with dementia and neuropsychiatric symptomology. However, the prognostic utility of circulating serotonin levels in detecting features of prodromal dementia including functional decline, cognitive impairment, mild behavioural impairment and brain atrophy remains unclear. In this prospective study of memory clinic subjects followed-up for ≤5 years, dementia-free subjects, classified as having no cognitive impairment or cognitive impairment, no dementia at baseline, underwent annual neuropsychological assessments including Montreal Cognitive Assessment, Global Cognition scores and Clinical Dementia Rating Scale Global Scores (where a ≥ 0.
View Article and Find Full Text PDFLipid-mediated resolution of inflammation and survival in amyotrophic lateral sclerosis.
Brain Commun
January 2025
Neuromuscular Department, Motor Neuron Disease Centre, Queen Square Institute of Neurology, University College London, London WC1N 3BG, UK.
Neuroinflammation impacts on the progression of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disorder. Specialized pro-resolving mediators trigger the resolution of inflammation. We investigate the specialized pro-resolving mediator blood profile and their receptors' expression in peripheral blood mononuclear cells in relation to survival in ALS.
View Article and Find Full Text PDFMeasurement properties of the German version of the Cambridge examination for mental disorders of older people with Down syndrome and others with intellectual disabilities (CAMDEX-DS).
J Intellect Dev Disabil
December 2024
Department of Neurology, University Hospital, LMU Munich, Germany.
Background: The CAMDEX-DS is an instrument to diagnose Alzheimer's disease (AD) in Down syndrome consisting of an informant interview and a cognitive test battery (CAMCOG-DS). Measurement properties of the German CAMDEX-DS were investigated.
Method: Fifty-five adults with Down syndrome (19-58 years) participated in this observational study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!